

## Sprint Bioscience's DCPS data published in Leukemia

**Sprint Bioscience today announces that results from its DCPS program have been published in *Leukemia*, a scientific journal from Nature and one of the leading publications in hematology and oncology. The study strengthens the validation of DCPS as a therapeutic target in the treatment of Acute Myeloid Leukemia (AML).**

The article identifies biomarkers associated with AML subtypes that respond particularly well to DCPS inhibition and sheds light on the underlying mechanisms of action. The results show that AML cases with DNMT3a and FLT3 ITD mutations and low levels of the related protein FHIT are particularly sensitive to DCPS inhibition. This facilitates patient selection and thereby increases the likelihood of positive treatment outcomes. Previous observations have shown that DCPS inhibitors have minimal impact on healthy cells and normal blood formation, with no signs of adverse effects.

"The potential for patient stratification combined with the favourable safety profile strengthens our conviction that DCPS inhibitors could become an effective and safe treatment option for AML," says Martin Andersson, CSO at Sprint Bioscience.

AML is a difficult-to-treat form of blood cancer in which current standard therapies—primarily chemotherapy—carry severe side effects and offer limited efficacy. Relapse is also common, underscoring the need for safer and more effective treatments.

The article is a collaboration between Sprint Bioscience AB, the research groups of Dr. Julian Walfridsson and Dr. Hong Qian at Karolinska Institutet, NeoTargets AB, and BioReperia AB. The Swedish Foundation for Strategic Research has partially funded it through an industrial PhD fellowship."

The article in *Leukemia* is available to read here: <https://www.nature.com/articles/s41375-025-02661-z>

**For further information, kindly contact:**

---

Johan Emilsson, CEO, Sprint Bioscience  
Tel: +46 (8) 411 44 55  
Epost: [johan.emilsson@sprintbioscience.com](mailto:johan.emilsson@sprintbioscience.com)

## About Sprint Bioscience AB (publ)

---

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website; [www.sprintbioscience.com](http://www.sprintbioscience.com). Certified Advisor is FNCA Sweden AB, [www.fnca.se](http://www.fnca.se).

## Attachments

---

[Sprint Bioscience's DCPS data published in Leukemia](#)